Spots Global Cancer Trial Database for met amplification

Every month we try and update this database with for met amplification cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC	NCT05800340	Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski...	Toripalimab Nab paclitaxel Pemetrexed Carboplatin	18 Years -	Guangdong Provincial People's Hospital
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer	NCT02609776	Non-Small-Cell ...	Amivantamab Amivantamab Lazertinib Carboplatin Pemetrexed	18 Years -	Janssen Research & Development, LLC
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC	NCT05800340	Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski...	Toripalimab Nab paclitaxel Pemetrexed Carboplatin	18 Years -	Guangdong Provincial People's Hospital
Study of Crizotinib for ROS1 and MET Activated Lung Cancer	NCT04084717	Non-squamous No... Stage IV Non-sm... ROS1 Gene Rearr... MET Activating ... MET Amplificati...	Crizotinib	18 Years -	University Health Network, Toronto
Lorlatinib Combinations in Lung Cancer	NCT04292119	Lung Cancer Anaplastic Lymp... ROS1 Rearrangem... Relapsed Cancer MET Amplificati... Resistant Cance... NSCLC	Lorlatinib Crizotinib Binimetinib TNO155	18 Years -	Massachusetts General Hospital
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	NCT03333343	EGFR-mutant Non...	EGF816 trametinib ribociclib LXH254 INC280 gefitinib	18 Years -	Novartis
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC	NCT06109558	Non Small Cell ... RET Gene Mutati... MET Amplificati... EGF-R Positive ...	LMV-12(HE003)	18 Years -	Hunan Province Tumor Hospital
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC	NCT05800340	Non-Small Cell ... RET Driver Muta... BRAF V600 Mutat... Erb-B2 Receptor... MET Amplificati... MET Exon 14 Ski...	Toripalimab Nab paclitaxel Pemetrexed Carboplatin	18 Years -	Guangdong Provincial People's Hospital
Tepotinib in Solid Tumors Harboring MET Alterations	NCT04647838	Solid Tumor MET Exon 14 Ski... MET Amplificati...	Tepotinib	19 Years -	Chungbuk National University Hospital
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC	NCT03333343	EGFR-mutant Non...	EGF816 trametinib ribociclib LXH254 INC280 gefitinib	18 Years -	Novartis
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	NCT04270591	C-Met Exon 14 M...	Glumetinib	18 Years - 80 Years	Haihe Biopharma Co., Ltd.
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	NCT04270591	C-Met Exon 14 M...	Glumetinib	18 Years - 80 Years	Haihe Biopharma Co., Ltd.
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC	NCT06109558	Non Small Cell ... RET Gene Mutati... MET Amplificati... EGF-R Positive ...	LMV-12(HE003)	18 Years -	Hunan Province Tumor Hospital
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)	NCT03944772	Non-Small Cell ...	Osimertinib Savolitinib Gefitinib Necitumumab Durvalumab Carboplatin Pemetrexed Alectinib Selpercatinib Selumetinib Etoposide Cisplatin Datopotamab der...	18 Years - 130 Years	AstraZeneca

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: